Answer
Palopegteriparatide (Yorvipath) has not been studied in people with severe kidney or severe liver impairment and should be used with caution in these populations.
Sources for this answer
- Yorvipath 294 micrograms/0.98 mL solution for injection in pre filled penAscendis Pharma UK Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 4Document updated
Sources checked